TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9851729
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies in patients with DM
Study: 2050832
Drug: Hydrochlorothiazide (HC)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HC) 72 +/- 26 mg/d
Study: 2050832
Drug: Spironolactone (SP)
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone (SP) 144 +/- 53 mg/d
Study: 6846677
Drug: Intensive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive group treatment procedures
Study: 30001258
Drug: High-dose folic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose folic acid (5 mg/wk)
Study: 30001258
Drug: Low-dose folic
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose folic acid (0.8 mg/wk)
Study: 29482433
Drug: Dengvaxia (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengvaxia (tetravalent live-attenuated 3-dose vaccine composed of chimeras of yellow fever 17D and the four dengue viruses)
Study: 24998405
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management without physical therapy
Study: 21623342
Drug: Demand-only PCEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Demand-only PCEA (0.125% levobupivacaine plus 1.5 mcg/mL fentanyl, 10 mL bolus with a 20 min lock time)
Study: 21623342
Drug: PCEA plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCEA plus background infusion (10 mL/h)
Study: 19874650
Drug: 1.6 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.6 mg/kg oral MDMA
Study: 19874650
Drug: 1.0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg/kg oral MDMA
Study: 17032096
Drug: Forgiveness Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forgiveness Therapy (FT)
Study: 17032096
Drug: Alternative Treatment
Normalized name: HERBS/ALTERNATIVE THERAPIES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative Treatment (AT)
Study: 15068419
Drug: L. brevis
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. brevis (CD2)
Study: 10647315
Drug: L‐NMMA (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐NMMA (6 mg/kg intravenous infusion)
Study: 15871635
Drug: Oral ganciclovir
Normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ganciclovir (1000 mg three times daily)
Study: 1610712
Drug: 1% crude
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% crude coal tar used twice daily for 10 days
Study: 6705284
Drug: Oral prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prenalterol at doses of 20, 40, 100, and 200 mg daily for four weeks
Study: 6705284
Drug: Oral prenalterol
Normalized name: prenalterol
DrugBank: Prenalterol (DB13777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prenalterol
Study: 30016948
Drug: Preventive Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive Physical Therapy (PPT)
Study: 23998969
Drug: OM3‐FFA 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3‐FFA 2 g/d
Study: 24528690
Drug: OM3‐FFA 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3‐FFA 3 g/d
Study: 23998969
Drug: OM3‐FFA 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3‐FFA 4 g/d
Study: 23998969
Drug: Control (olive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (olive oil [OO] 4 g/d)
Study: 23171601
Drug: Worry intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Worry intervention (cognitive-behavioral treatment)
Study: 26537725
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (treatment as usual)
Study: 10207545
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) monotherapy and combination arms
Study: 10445104
Drug: Gonadotropins (GN)
Normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropins (GN) combined with growth hormone (GH) for 6 months
Study: 2142930
Drug: Gestodene-containing formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestodene-containing formulation
Study: 2142930
Drug: Desogestrel-containing formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel-containing formulation
Study: 902005
Drug: Counselling on
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: Counselling on medication errors
Study: 902005
Drug: Tear-off daily
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tear-off daily calendar
Study: 902005
Drug: Pill wheel
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pill wheel
Study: 30862265
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (EVT) for transferred patients
Study: 26458813
Drug: Titanium Grade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium Grade IV (Ti Grade IV) implants
Study: 23992793
Drug: General therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: General therapy skills (feedback and understanding)
Study: 21574351
Drug: Vacuum-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vacuum-assisted therapy (V.A.C. Therapy system)
Study: 21574351
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (including debridement)
Study: 19121493
Drug: Sandblasting +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasting + silane-coupling agent (Group 2)
Study: 19121493
Drug: Tribochemical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribochemical treatment (Group 3)
Study: 16713778
Drug: Midazolam (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (7 mg)
Study: 16713778
Drug: Etomidate (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (20 mg)
Study: 11312014
Drug: Monovalent dengue
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent dengue vaccines (dengue-1, dengue-2, dengue-3, dengue-4)
Study: 11312014
Drug: Vaccine vehicle
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine vehicle (control)
Study: 11312014
Drug: All dengue-3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: All dengue-3, dengue-4, and tetravalent vaccine recipients
Study: 11312014
Drug: Dengue-1 and
Normalized name: dengue virus live antigen, CYD serotype 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue-1 and dengue-2 vaccine recipients
Study: 11312014
Drug: Dengue-2, dengue-3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dengue-2, dengue-3, dengue-4, and 60% of dengue-1 vaccine recipients
Study: 11312014
Drug: Tetravalent vaccine
Normalized name: DENGUE TETRAVALENT VACCINE,LIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetravalent vaccine recipients
Study: 9250115
Drug: Oat-bran test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat-bran test meal (16.3 g fiber)
Study: 9250115
Drug: Wheat test
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat test meal (6.3 g fiber)
Study: 7945494
Drug: Corticosteroids (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (0.5 mg/kg of prednisone daily)
Study: 27181755
Drug: Standard Diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Diabetes Manual + Diabetes Treatment Guide + 30-min seminar
Study: 27181755
Drug: Diabetes Treatment
Normalized name: Diabetes Ancillary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Treatment Guide only
Study: 25916420
Drug: Audible music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Audible music group (MG)
Study: 30336703
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone (50 mg daily)
Study: 20537615
Drug: Implant naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant naltrexone (2.3 g single dose)
Study: 20537615
Drug: Blood naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood naltrexone concentration < 0.5 ng/mL
Study: 20537615
Drug: Blood naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood naltrexone concentration 3 ng/mL
Study: 20537615
Drug: Implant naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant naltrexone
Study: 20482515
Drug: Oral naltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral naltrexone
Study: 20537615
Drug: Noncompliance with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncompliance with daily oral formula, higher baseline craving, longer history of use, being younger
Study: 18672743
Drug: Abdominal acupuncture
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal acupuncture (n = 23), administered once daily for the first three days and once every three days for the remaining 11 days, plus placebo pill once daily
Study: 1781820
Drug: Prednisone 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone 1.5 mg/kg/d
Study: 28129492
Drug: Topiramate (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25-200 mg/d for 12 weeks)
Study: 26239090
Drug: High-dose UFH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose UFH (100 U/kg bolus followed by age-based continuous infusion)
Study: 26239090
Drug: Low-dose UFH
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose UFH (50 U/kg bolus)
Study: 26239090
Drug: UFH dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFH dose and effect
Study: 16311083
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of octreotide and methylglucamine diatrizoate
Study: 11757832
Drug: Ciprofloxacin +
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin + rifampicin (50 mg/L each)
Study: 11757832
Drug: Cephradine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephradine (250 mg/L)
Study: 9048273
Drug: Fantofarone 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone 100 mg twice daily
Study: 9048273
Drug: Fantofarone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone 150 mg twice daily
Study: 9048273
Drug: Fantofarone (100-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone (100-150 mg twice daily)
Study: 9048273
Drug: Fantofarone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fantofarone (all doses)
Study: 8151104
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of OA
Study: 8151104
Drug: 20 g
Normalized name: PEG-20 glyceryl oleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 g of OA
Study: 8151104
Drug: 40 g
Normalized name: PEG-40 GLYCERYL STEARATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 g of OA
Study: 3529043
Drug: Experimental treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatments affecting incidence of S. aureus contamination
Study: 24556040
Drug: Dovitinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dovitinib (500 mg orally, 5 days on and 2 days off)
Study: 22270258
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg orally twice daily)
Study: 23174050
Drug: 3% SIG1273
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% SIG1273 gel
Study: 16430546
Drug: Bupivacaine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (12 mg) + Dexmedetomidine (3 microg)
Study: 16430546
Drug: Bupivacaine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (12 mg) + Clonidine (30 microg)
Study: 9254267
Drug: Magnetothermia combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetothermia combined with chemotherapy using fluorouracil
Study: 9254267
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with fluorouracil
Study: 24497220
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg/day
Study: 26643687
Drug: Educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educational program (G-I, n = 137)
Study: 26643687
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (G-II, n = 119)
Study: 22969230
Drug: Composite yogurt
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite yogurt enriched with acacia dietary fiber and Bifidobacterium lactis (B. lactis), consumed twice daily for 8 weeks
Study: 19027263
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus followed by 0.25 mg/kg per hour continuous infusion)
Study: 19027263
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 mg/kg bolus followed by 0.25 mg/kg per hour continuous infusion)
Study: 11158748
Drug: Intrarectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrarectal artesunate (10 mg/kg)
Study: 11158748
Drug: Intrarectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intrarectal artesunate (20 mg/kg)
Study: 9266868
Drug: Albuterol every
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol every 30 min (group 1, n=34)
Study: 9266868
Drug: Albuterol every
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol every 60 min (group 2, n=33)
Study: 9266868
Drug: Albuterol every
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol every 120 min (group 3, n=33)
Study: 9266868
Drug: Albuterol treatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol treatment for low responders (<15 percentage point increase at 15 min)
Study: 9266868
Drug: Albuterol treatment
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol treatment for high responders (>15 percentage point increase at 15 min)
Study: 3810772
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (high normal hemoglobin concentration, 15 g/l or more)
Study: 3810772
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy (lower hemoglobin concentration, less than 15 g/l)
Study: 3810772
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (extracranial‐intracranial bypass)
Study: 27687417
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate 20 mg/kg in bolus followed by magnesium 2 mg kg(‐1) h(‐1) (group M)
Study: 27687417
Drug: Intravenous ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ketorolac 30 mg in bolus followed by saline infusion (group K)
Study: 27687417
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline solution 20 mL in bolus followed by saline infusion during the entire procedure (group S)
Study: 24320907
Drug: L-arginine dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine dietary supplement (3g)
Study: 12727949
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg continuous estradiol with 10 mg medroxyprogesterone acetate
Study: 12727949
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg continuous estradiol with 10 mg medroxyprogesterone acetate
Study: 6397328
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 200 mg injection every 60 +/‐ 5 days
Study: 6397328
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 200 mg injection every 90 +/‐ 5 days
Study: 6397328
Drug: Norethisterone oenanthate
Normalized name: Oenanthic acid
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone oenanthate (NET OEN) 200 mg injection
Study: 25753514
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination treatment with fractional CO2 laser plus topical betamethasone solution and narrowband ultraviolet B
Study: 25753514
Drug: Control side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control side received laser treatment plus phototherapy
Study: 19744725
Drug: Interferon (IFN)‐alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐alfa‐2a treatment (3 MIU subcutaneously 3 times per week for 2 years)
Study: 19744725
Drug: Interferon (IFN)‐alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)‐alfa‐2a treatment
Study: 11734652
Drug: Androgen ablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen ablative therapy
Study: 25997425
Drug: High serum
Approvals — FDA: no, EMA: no, PMDA: no
Description: High serum NT-proBNP level on hospital admission (≥ 2,563.6 pg/ml)
Study: 23538435
Drug: galyfilcon A/polyhexanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: galyfilcon A/polyhexanide (combination 1)
Study: 23538435
Drug: balafilcon A/polyquaternium‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: balafilcon A/polyquaternium‐1 and myristamidopropyl dimethylamine + TearGlyde (combination 2)
Study: 20619623
Drug: Indacaterol 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 600 μg
Study: 12472345
Drug: 4% hydroquinone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% hydroquinone cream combined with glycolic acid peels
Study: 30958285
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (3 sessions, once every 4-5 days)
Study: 30958285
Drug: Combined extracorporeal
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined extracorporeal shock wave therapy (3 sessions, once every 4-5 days) and local use of silicone gel Strataderm
Study: 15545060
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (800 microg of budesonide) for 12 weeks
Study: 11244659
Drug: Thermal balloon
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thermal balloon ablation therapy
Study: 12297711
Drug: Gestagen therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gestagen therapy
Study: 9850017
Drug: Short chemotherapy
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short chemotherapy (6 months) with vincristine and dactinomycin (pulse-intensive)
Study: 9850017
Drug: Long chemotherapy
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long chemotherapy (9 additional months) with vincristine and dactinomycin (pulse-intensive)
Study: 9850017
Drug: Short PI
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short PI treatment regimens
Study: 1078711
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (control)
Study: 30544793
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group (received free vision care and eyeglasses)
Study: 30544793
Drug: Treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group membership
Study: 26758402
Drug: Captopril 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 1% ointment
Study: 19866403
Drug: 3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg of oral sildenafil every 6 hours
Study: 18416077
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment for one month at main points (Zhongwan (CV 12), Zusanli (ST 36), Taichong (LR 3), Shenmen (HT 7))
Study: 18416077
Drug: Domperidone orally
Normalized name: Domperidone
DrugBank: Domperidone (DB01184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domperidone orally administered for one month
Study: 16938781
Drug: Second identical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second identical cochlear implant in the contralateral ear immediately
Study: 1452964
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg dietary calcium per day
Study: 1452964
Drug: 1,500 mg
Normalized name: garlic 1,500 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,500 mg dietary calcium per day
Study: 26591358
Drug: Chinese medicine
Normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese medicine (CM) group - WYHZTLR decoction (one dose per day)
Study: 26591358
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine (WM) group - penicillamine tablet (0.125 g, bid) and Prednisone Acetate Tablet (PAT 20 mg, qd)
Study: 26591358
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine (IM) group - penicillamine, PAT, and WYHZTLR decoction (same dosages as above)
Study: 19232061
Drug: Background therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Background therapy and/or early rescue
Study: 10566728
Drug: SP-303 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP-303 (500 mg p.o. every 6 h for 96 h)
Study: 8729191
Drug: Tamoxifen (endocrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (endocrine therapy)